IPCA Labs

IPCA now plus Rs.2700 Crores Company is global player with significant presence in over 110 countries with high brand equity in the domestic and international markets Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

Ipca is a fully integrated, rapidly growing Indian pharmaceutical company with a strong thrust on exports. Ipca's APIs and Formulations produced at worldclass manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA). With operations in over 100 countries, exports account for over 52%  of the company's income.

Ipca is a fully integrated, rapidly growing Indian pharmaceutical company with a strong thrust on exports. Ipca's APIs and Formulations produced at worldclass manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA). With operations in over 100 countries, exports account for over 52%  of the company's income.

IPCA now plus Rs.2700 Crores Company is global player with significant presence in over 110 countries with high brand equity in the domestic and international markets Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

IPCA now plus Rs.2700 Crores Company is global player with significant presence in over 110 countries with high brand equity in the domestic and international markets Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

IPCA now plus Rs.2700 Crores Company is global player with significant presence in over 110 countries with high brand equity in the domestic and international markets
Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

IPCA now plus Rs.2700 Crores Company is global player with significant presence in over 110 countries with high brand equity in the domestic and international markets Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

IPCA now plus Rs.2700 Crores Company is global player with significant presence in over 110 countries with high brand equity in the domestic and international markets Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

Ipca has been continuously evolving as an integrated pharmaceutical company over 65 years. Ipca has an annual turnover in excess of Rs.3,120 Crores with over 350 formulations and 80 APIs for various therapeutic segments. We are committed to Research & Development and expanding our R&D capabilities to build a strong future. cGMP (current Good Manufacturing Practices) & Safety is a way of life. We are committed to further enhance cGMP and safety journey on continuous basis to deliver safe and quality products for mankind and to build a safe workplace for our employees. Our manufacturing facilities of bulk drugs at Ratlam have earned accreditations and approvals from the worlds most vigilant regulatory bodies.

Post : QC, QA, Engineering